Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TYMS | P04818 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Fluorodeoxyuridylate SCHEMBL973436 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL17117772 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL21901970 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15189164 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491971 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| SCHEMBL13026822 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15671694 | 0.92 | TYMS (0.64) | LMNASMN1; SMN2TYMS | |
| SCHEMBL28378385 | 0.92 | LMNA (0.66) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL25223991 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491976 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3461 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | claimed |
| US-20250360157-A1 | CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF | Wake Forest Univesity Health Sciences (US) | 2025-11-27 | — | — | US | claimed |
| US-20250262215-A1 | USE OF CYCLIN E1 STATUS AS A PREDICTIVE BIOMARKER FOR TREATING CANCER WITH WEE1 INHIBITORS | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250205217-A1 | METHODS OF IMPROVING CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-26 | — | — | US | claimed |
| US-12319915-B2 | Cytotoxic fluoropyrimidine polymers and methods of use thereof | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2025-06-03 | — | — | US | claimed |
| CN-119744179-A | Conjugates for targeted therapy | 梁碧惠 | 2025-04-01 | — | — | CN | claimed |
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| EP-4504267-A1 | CONJUGATE FOR TARGETING THERAPY | National Taiwan University (TW) | 2025-02-12 | — | — | EP | claimed |
| WO-2003068223-A1 | ARYL UREAS WITH RAF KINASE AND ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003068229-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-5663321-A | INHIBITOR OF THYMIDYLATE SYNTHASE; ANTICANCER/ANTITUMOR AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-09-02 | — | — | US | claimed |
| US-5614505-A | 5-FLUOROURIDINE OR 5-FLUORODEOXYURIDINE, DRUG DELIVERY, IMPROVED BIOAVAILABILITY, ANTICARCINOGENIC AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-03-25 | — | — | US | claimed |
| US-5457187-A | Antitumor, anticarcinogeic agents | BOARD OF REGENTS UNIVERSITY OF NEBRASKA (US) | 1995-10-10 | — | — | US | claimed |